RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Rapport Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$28.60+1.03 (+3.74%)
Close on Oct 19, 2026
- Market cap
- $1.36B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$3.61 (+14.45%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.36B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.21
- Dividend yield
- –
- Free cash flow yield
- -7.16%
Fundamentals
- Net income
- -$137.16M
- EPS, diluted
- -$3.04
- Free cash flow
- -$97.15M
- Book value per share
- $8.91
- Diluted shares
- 47M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$153.52M
Net income
-$137.16M
EPS, diluted
-$3.04
Free cash flow
-$97.15M
Reported periodTrailing twelve months